Secondary Logo

Journal Logo

Current World Literature

Current Opinion in Supportive and Palliative Care: June 2009 - Volume 3 - Issue 2 - p 144–151
doi: 10.1097/SPC.0b013e32832c6adb
Current World Literature: Bibliography

This bibliography is compiled by clinicians from the journals listed at the end of this publication. It is based on literature entered into our database between 1 March 2008 and 28 February 2009 (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

• Papers considered by the reviewers to be of special interest

•• Papers considered by the reviewers to be of outstanding interest

The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review.

Back to Top | Article Outline

Respiratory problems

Noisy respiratory secretions at the end of life

Review: (pp. 120–124)

Barbas CSV, Icu A. The complex issue of a simple suctioning maneuver in acute respiratory distress syndrome. Crit Care Med 2008; 36:644–645.

Chang AB, Redding GJ, Everard ML. Chronic wet cough: Protracted bronchitis, chronic suppurative lung disease and bronchiectasis [Review]. Pediatr Pulmonol 2008; 43:519–531.

Graf J, Marini JJ. Do airway secretions play an underappreciated role in acute respiratory distress syndrome? [Review]. Curr Opin Crit Care 2008; 14:44–49.

Kamin W. Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr 2008; 97:57–60.

Nin T, Umemoto M, Negoro A, Miuchi S, et al. Nizatidine enhances salivary secretion in patients with dry mouth. Auris Nasus Larynx 2008; 35.

Raval TH, Elliott CA. Botulinum toxin injection to the salivary glands for the treatment of sialorrhea with chronic aspiration. Ann Otol Rhinol Laryngol 2008; 117.

•• Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev 2008:CD005177.[03]

• Wildiers H, Demeulenaere P, Clement P, Menten J. Treatment of death rattle in dying patients. Belgian J Med Oncol 2008; 2:275–279.[06]

Back to Top | Article Outline

Physiologic changes and clinical correlates of advanced dyspnea

Review: (pp. 93–97)

Allred L, Ruiz R, Jones D, Donn SM. Intractable respiratory failure in a term newborn. Am J Perinatol 2008; 25:101–103.

Baggish AL, van Kimmenade RRJ, Januzzi JL. Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. Am J Cardiol 2008; 101:49A–55A.

• Banzett RB, Pedersen SH, Schwartzstein RM, Lansing RW. The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. Am J Respir Crit Care Med 2008; 177:1384–1390.[07]

Bao X, Sinha M, Liu T, Hong C, et al. Identification of human metapneumovirus-induced gene networks in airway epithelial cells by microarray analysis [Review]. Virology 2008; 374:114–127.

Baron M, Sutton E, Hudson M, Thombs B, et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 2008; 67:644–650.

Collier DJ, Nickol AH, Milledge JS, van Ruiten HJA, et al. Alveolar PCO2 oscillations and ventilation at sea level and at high altitude. J Appl Physiol 2008; 104:404–415.

Eberlein MH, Drummond MB, Haponik EF. Plastic bronchitis: A management challenge. Am J Med Sci 2008; 335:163–169.

Evrard F, Dupuis M, Muller T, Jacquerye P. Isolated pulmonary hypertension and pergolide [French]. Rev Neurol (Paris) 2008; 164:278–279.

Gargani L, Frassi F, Soldati G, Tesorio P, et al. Ultrasound lung comets for the differential diagnosis of acute cardiogenic dyspnoea: A comparison with natriuretic peptides. Eur J Heart Fail 2008; 10:70–77.

Han JN, Zhu YJ, Li SW, Zhang J, et al. The language of medically unexplained Dyspnea. Chest 2008; 133:961–968.

Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, et al. Dyspnea experience in patients with lung cancer in palliative care. Eur J Oncol Nurs 2008; 12:86–96.

Jiang-Na H, Yuan-Jue Z, Dong-Mei L, Shun-Wei L, et al. Fearful imagery induces hyperventilation and dyspnea medically unexplained dyspnea. Chin Med J 2008; 121:56–62.

Kalhoff H, Lara E, Kiwull P, Kiwull-Schone H. Patterns of intrathoracic gas volume and airway resistance in children with asthma. J Physiol Pharmacol 2007; 58:307–312.

Karapolat H, Eyigor S, Atasever A, Zoghi M, et al. Effect of dyspnea and clinical variables on the quality of life and functional capacity in patients with chronic obstructive pulmonary disease and congestive heart failure. Chin Med J 2008; 121:592–596.

Karbing DS, Kjaergaard S, Smith BW, Espersen K, et al. Variation in the PaO2/FiO(2) ratio with FiO2: mathematical and experimental description, and clinical relevance - art. no. R118. Crit Care 2007; 11:R118.

Katz U, Shoenfeld Y. Pulmonary eosinophilia [Review]. Clin Rev Allergy Immunol 2008; 34:367–371.

Khandaker MH, Knoll BA, Arora AS. 63-year-old man with cryptogenic cirrhosis and dyspnea. Mayo Clin Proc 2008; 83:580–583.

Kirkpatrick JN, Ghani SN, Spencer KT. Hand carried echocardiography screening for LV systolic dysfunction in a pulmonary function laboratory. European Journal of Echocardiography 2008; 9:381–383.

Koethe JR, Chang AY. Dyspnea and hemoptysis in a 53-year-old woman with a history of breast cancer. Chest 2008; 133:1248–1251.

•• Lansing RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnea: review and hypotheses. Respir Physiol Neurobiol 2008. [Epub ahead of print][27]

Min X, Xian-Sheng L, Yong-Jian X, Zhen-Xiang Z, et al. Role of the extracellular signal-regulated kinase 1/2 signaling pathway in regulating the secretion of bronchial smooth muscle cells in a rat model of chronic asthma. Chin Med J 2008; 121:73–77.

Morell F, Roger A, Reyes L, Cruz MJ, et al. Bird fancier's lung - A series of 86 patients [Review]. Medicine 2008; 87:110–130.

Muhlfeld C, Rothen-Rutishauser B, Blank F, Vanhecke D, et al. Interactions of nanoparticles with pulmonary structures and cellular responses [Review]. Am J Physiol-Lung Cell Mol Physiol 2008; 294:L817–L829.

Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: A review [Review]. Semin Nucl Med 2008; 38:167–176.

•• O'Donnell DE, Banzett RB, Carrieri-Kohlman V, Casaburi R. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007; 4:145–168.[15]

Ofir D, Laveneziana P, Webb KA, Lam YM, et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:622–629.

Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: Analytic considerations. Am J Cardiol 2008; 101:9A–15A.

Patel K, Shankar V, Plambeck CJ, Pagel PS. Progressive dyspnea and exercise intolerance in an adult with a persistent childhood murmur. J Cardiothorac Vasc Anesth 2008; 22:157–159.

Peiffer C. Dyspnea and emotion - What can we learn from functional brain imaging? Am J Respir Crit Care Med 2008; 177:937–939.

Peiffer C, Costes N, Herve P, Garcia-Larrea L. Relief of dyspnea involves a characteristic brain activation and a specific quality of sensation. Am J Respir Crit Care Med 2008; 177:440–449.

Qin XJ, Li YN, Liang X, Wang P, et al. The dysfunction of ATPases due to impaired mitochondrial respiration in phosgene-induced pulmonary edema. Biochem Biophys Res Commun 2008; 367:150–155.

Reid JM, Forster A, Fitch PS, Smith FW, et al. An atypical case of neuralgic amyotrophy with respiratory muscle weakness: Case report and review of literature. Scott Med J 2008; 53:13–15.

Schafer A, Kratky KW. Estimation of breathing rate from respiratory sinus arrhythmia: Comparison of various methods. Ann Biomed Eng 2008; 36:476–485.

Scichilone N, Paglino G, Battaglia S, Martino L, et al. The mini nutritional assessment is associated with the perception of dyspnoea in older subjects with advanced COPD. Age Ageing 2008; 37:214–217.

Swingler GH, Zwarenstein M. Chest radiograph in acute respiratory infections - art. no. CD001268 [Review]. Cochrane Database of Systematic Reviews 2008:1268.

von Leupoldt A, Sommer T, Kegat S, Baumann HJ, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med 2008; 177:1026–1032.

Wadhwa H, Gradinaru C, Gates GJ, Badr MS, et al. Impact of intermittent hypoxia on long-term facilitation of minute ventilation and heart rate variability in men and women: do sex differences exist? J Appl Physiol 2008; 104:1625–1633.

Wilson K, Widdowson M, Swanney M, Meyer R, et al. Chronic dyspnea and wheezing in a 46-year-old nonsmoker. Chest 2008; 133:1034–1037.

Yango J, Pieters T, Coche E, Lambert M. Increased serum CA 19.9 in bronchiectasis [French]. Rev Mal Respir 2008; 25:78–81.

Yao X, Gilmore E, Nugent K. A 46-year-old man with dyspnea, dysphagia, and pulmonary hypertension. Chest 2008; 133:812–815.

Young RL, Mitchell JD, Cool C, Nana-Sinkam SP. Wheezing and exertional dyspnea in a 25-year-old mountaineer. Chest 2008; 133:820–825.

Back to Top | Article Outline

Pulmonary rehabilitation for dyspnea in the palliative-care setting

Review: (pp. 112–119)

• Ambrosino N, Casaburi R, Ford G, et al. Developing concepts in the pulmonary rehabilitation of COPD. J Respir Med 102(suppl 1); 2008:S17–S26.[21]

Banzett RB, Pedersen SH, Schwartzstein RM, Lansing RW. The affective dimension of laboratory dyspnea: Air hunger is more unpleasant than work/effort. Am J Respir Crit Care Med 2008; 117:1384–1390.

• Collins EG, Langbein WE, Fehr L, et al. Can ventilation-feedback training augment exercise tolerance in patients with chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2008; 177:844–852.[16]

•• Dolmage TE, Goldstein RS. Effects of one-legged exercise training of patients with COPD. Chest 2008; 133:370–376.[15]

• du Moulin M, Taube K, Wegscheider K, et al. Home-based exercise training as maintenance after outpatient pulmonary rehabilitation. Respiration published online July 31, 2008 (DOI:10.1159/000150315).[34]

Ingle L. Prognostic value and diagnostic potential of cardiopulmonary exercise testing in patients with chronic heart failure [Review]. Eur J Heart Fail 2008; 10:112–118.

Jensen D, Amjadi K, Harris-McAllister V, Webb KA, et al. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax 2008; 63:606–613.

•• Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2008; 149:869–878.[40]

• Ries AL, Make BJ, Reilly JJ. Pulmonary rehabilitation in emphysema. Proc Am Thorac Soc 2008; 5:524–529.[44]

• Vivodtzev I, Lacasse Y, Maltais F. Neuromuscular electrical stimulation of the lower limbs in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev 2008; 28:79–91.[26]

• Wewel AR, Gellerman I, Schwertfeger I, et al. Intervention by phone calls raises domiciliary activity and exercise capacity in patients with severe COPD. Respir Med 2008; 102:20–26.[37]

Back to Top | Article Outline

Nonpharmacological management of dyspnea

Review: (pp. 98–102)

7th French language meeting on alveolates - Dyspnea exercise and chronic diseases - Lyon, 14-15 March 2008 - Abstracts [French]. Rev Mal Respir 2008; 25:627–648.

•• Bausewein C, Booth S, Gysels M, Higginson I. Nonpharmacological interventions for breathlessness in advanced stages of malignant and nonmalignant diseases. Cochrane Database Syst Rev 2008:CD005623.[28]

Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L, et al. Interventions for alleviating cancer-related dyspnea: A systematic review [Review]. J Clin Oncol 2008; 26:2396–2404.

Cachia E, Ahmedzai SH. Breathlessness in cancer patients. Eur J Cancer 2008; 44:1116–1123.

Claseem A, Snow V, Shekelle P, Casey DE, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: A clinical practice guideline from the American college of physicians. Ann Intern Med 2008; 148:141–146.

Clemens KE, Klaschik E. Morphine in the management of dyspnoea in ALS. A pilot study. Eur J Neurol 2008; 15:445–450.

Combes A, Leprince P, Luyt CE, Bonnet N, et al. Outcomes and long-term quality-of-life of patients supported by extyacorpoyeal membrane oxygenation for refractory caydiogenic shock. Crit Care Med 2008; 36:1404–1411.

•• Crisafulli E, Costi S, De Blasio F, et al. Effects of a walking aid in COPD patients receiving oxygen therapy. Chest 2007; 131:1068–1074.[18]

Di Salvo WM, Joyce MM, Tyson LB, Culkin AE, et al. Putting evidence into Practice (R): Evidence-based interventions for cancer-related dyspnea. Clin J Oncol Nurs 2008; 12:341–352.

Frances MEM, Tordera MP, Fuster AB, Moragon EMM, et al. Impact of baseline and induced dyspnea on the quality of life of patients with COPD [Spanish]. Arch Bronconeumol 2008; 44:127–134.

Frassi F, Gargani L, Picano E. Prognostic value of extravascular lung water assessed with ultrasound lung comets by chest sonography in patients with dyspnea and/or chest pain. J Card Fail 2008; 14:264–265.

Galie N, Olschewski H, Oudiz RJ, Torres F, et al. Ambrisentan for the treatment of pulmonary arterial hypertension - Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 2008; 117:3010–3019.

Gonzalez CM. The role of the pulmonologist in the assessment of disability in patients with respiratory disease [Review] [Spanish]. Arch Bronconeumol 2008; 44:204–212.

Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, et al. Dyspnea experience in patients with lung cancer in palliative care. Eur J Oncol Nurs 2008; 12:86–96.

Hofstra JJH, Juffermans NP, Schultz MJ, Zweers MM. Pulmonary coagulopathy as a new target in lung injury - A review of available pre-clinical models [Review]. Current Medicinal Chemistry 2008; 15:588–595.

Karemaker R, Kavelaars A, ter Wolbeek M, Tersteeg-Kamperman M, et al. Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age. Pediatrics 2008; 121:E870–E878.

Kauser F, Legrand SB. Theophylline for unexplained dyspnea in palliative medicine: A case report. J Palliat Med 2008; 11:510–513.

Kissoon N, Rimensberger PC, Bohn D. Ventilation strategies and adjunctive therapy in severe lung disease [Review]. Pediatr Clin North Am 2008; 55:709.

Lavietes MH, Ameh J, Cherniack NS. Dyspnea and symptom amplification in asthma. Respiration 2008; 75:158–162.

Masterton RG, Galloway A, French G, Street M, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy [Review]. J Antimicrob Chemother 2008; 62:5–34.

Meyer T, Dullinger JS, Muench C, Keil JP, et al. Elective termination of respiratory therapy in amyotrophic lateral sclerosis [German]. Nervenarzt 2008; 79:684–690.

Muers MF, Stephens RJ, Fisher P, Darlison L, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371:1685–1694.

Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis [Review]. Respir Med 2008; 102:1–9.

Poupard L, Mathieu M, Sartene R, Goldman M. Use of thoracic impedance sensors to screen for sleep-disordered breathing in patients with cardiovascular disease. Physiol Meas 2008; 29:255–267.

Prasad SA, Main E, Dodd ME. Finding consensus on the physiotherapy management of asymptomatic infants with cystic fibrosis. Pediatr Pulmonol 2008; 43:236–244.

Reiner R. Integrating a portable biofeedback device into clinical practice for patients with anxiety disorders: Results of a pilot study. Applied Psychophysiology and Biofeedback 2008; 33:55–61.

Reittinger TM, Kaufman SR, Saint S. What effect does an educational intervention have on interns' confidence and knowledge regarding acute dyspnea management? A randomized controlled trial. J Hosp Med 2006; 1:339–343.

Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults - art. no. CD004418 [Review]. Cochrane Database of Systematic Reviews 2008:4418.

Shumway NM, Wilson RL, Howard RS, Parker JM, et al. Presence and treatment of air hunger in severely ill patients. Respir Med 2008; 102:27–31.

Singh D, Brooks J, Hagan G, Cahn A, et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63:592–598.

Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases [Review]. Int J Nanomed 2008; 3:1–19.

Stege G, Vos PJE, van den Elshout FJJ, Dekhuijzen PNR, et al. Sleep, hypnotics and chronic obstructive pulmonary disease [Review]. Respir Med 2008; 102:801–814.

Unger S, Cunningham S. Effect of oxygen supplementation on length of stay for infants hospitalized with acute viral bronchiolitis. Pediatrics 2008; 121:470–475.

Uronis HE, Currow DC, McCrory DC, Samsa GP, et al. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis [Review]. Br J Cancer 2008; 98:294–299.

van den Broek KM, Wielders PLML, Creemers JPHM, Smeenk FWJM. Efficacy of formoterol Turbuhaler in the emergency treatment of patients with obstructive airway diseases. Respir Med 2008; 102:579–585.

Viola R, Kiteley C, Lloyd NS, Mackay JA, et al. The management of dyspnea in cancer patients: a systematic review [Review]. Support Care Cancer 2008; 16:329–337.

Whale CI, Sovani MP, Mortimer KJ, Harrison TW, et al. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study. Br J Clin Pharmacol 2008; 65:841–847.

Yamasawa H, Sugiyama Y, Bando M, Ohno S. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration 2008; 75:350–354.

Yilmaz M, Gajic O. Optimal ventilator settings in acute lung injury and acute respiratory distress syndrome [Review]. Eur J Anaesthesiol 2008; 25:89–96.

Back to Top | Article Outline

Lung volume reduction surgery for the management of refractory dyspnea in chronic obstructive pulmonary disease

Review: (pp. 107–111)

•• Criner GJ, Sternberg AL National Emphysema Treatment Trial Research Group. A clinician's guide to the use of lung volume reduction surgery. Proc Am Thorac Soc 2008; 5:461–467.[05]

• Hersh CP, De Meo DL, Reilly JJ, Silverman EK. Xenobiotic metabolizing enzyme gene polymorphisms predict response to lung volume reduction surgery. Respir Res 2007; 8:59.[20]

• Lederer DJ, Thomashow BM, Ginsburg ME, et al. Lung-volume reduction surgery for pulmonary emphysema: improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 year. J Thorac Cardiovasc Surg 2007; 133:1412–1413.[13]

Maruscak AA, Vockeroth DW, Girardi B, Sheikh T, et al. Alterations to surfactant precede physiological deterioration during high tidal volume ventilation. Am J Physiol-Lung Cell Mol Physiol 2008; 294:L974–L983.

• Meyers BF, Sultan PK, Guthrie TJ, et al. Outcomes after unilateral lung volume reduction. Ann Thorac Surg 2008; 86:204–211. discussion 211–212[08]

• Mineo D, Ambrogi V, Frasca L, et al. Effects of lung volume reduction surgery for emphysema on glycolipidic hormones. Chest 2008; 134:30–37.[16]

Nioutsikou E, Seppenwoolde Y, Symonds-Tayler JRN, Heijmen B, et al. Dosimetric investigation of lung tumor motion compensation with a robotic respiratory tracking system: An experimental study. Med Phys 2008; 35:1232–1240.

• Snyder ML, Goss CH, Neradilek B, et al. Changes in arterial oxygenation and self-reported oxygen use after lung volume reduction surgery. Am J Respir Crit Care Med 2008; 178:339–345.[11]

• Tacconi F, Pompeo E, Forcella D, et al. Lung volume reduction reoperations. Ann Thorac Surg 2008; 85:1171–1177.[06]

Volpicelli G. Are ultrasound lung comets useful as prognostic indicator in any patients with dyspnea or chest pain? J Card Fail 2008; 14:263–264.

•• Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 177:130–131.[10]

Back to Top | Article Outline

Advances in the pharmacological management of breathlessness

Review: (pp. 103–106)

Balion CM, Santaguida P, McKelvie R, Hill SA, et al. Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. Clin Biochem 2008; 41:231–239.

• Ben-Aharon I, Gafter-Gvili A, Paul M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008; 26:2396–2404.[12]

Caprio AJ, Hanson LC, Munn JC, Williams CS, et al. Pain, dyspnea, and the quality of dying in long-term care. J Am Geriatr Soc 2008; 56:683–688.

Christ M, Laule K, Klima T, Hochholzer W, et al. Multimarker strategy for risk prediction in patients presenting with acute dyspnea to the emergency department. Int J Cardiol 2008; 126:73–78.

Goodlin SJ, Wingate S, Pressler SJ, Teerlink JR, et al. Investigating pain in heart failure patients: Rationale and design of the pain assessment, incidence & nature in heart failure (PAIN-HF) study. J Card Fail 2008; 14:276–282.

Green SM, Martinez-Rumayor A, Gregory SA, Baggish AL, et al. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 2008; 168:741–748.

Gross N, Levin D. Primary care of the patient with chronic obstructive pulmonary disease - Part 2: Pharmacologic treatment across all stages of disease. Am J Med 2008; 121:S13–S24.

MacFadyen RJ, Chuen MJNK. Blomarker sensitivity and specificity require pre-test probability of disease diagnosis to be collated: Additional points on the interpretation of pro-B-type natriuretic peptide triage of dyspnea in the Copenhagen Heart Study. J Am Coll Cardiol 2008; 51:1322–1323.

Manali ED, Stathopoulos GT, Kollintza A, Katomenidis I, et al. The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir Med 2008; 102:586–592.

Mogelvang R, Goetze JP, Schnohr P, Lange P, et al. Blomarker sensitivity and specificity require pre-test probability of disease diagnosis to be collated: Additional points on the interpretation of pro-B-type natriuretic peptide triage of dyspnea in the Copenhagen Heart Study - Reply. J Am Coll Cardiol 2008; 51:1323.

• Moosavi SH, Binks AP, Lansing RW, et al. Effect of inhaled furosemide on air hunger induced in healthy humans. Resp Phys Neurobiol 2007; 156:1–8.[20]

• Newton PJ, Davidson PM, Macdonald P, et al. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage 2008; 36:424–441.[21]

Pang PS, Cleland JGF, Teerlink JR, Collins SP, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008; 29:816–824.

Perez-Padilla R. Hidden respiratory disease-associated deaths. Int J Tuberc Lung Dis 2008; 12:458–464.

Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL. Independent and incremental prognostic value of multimarker testing in acute dyspnea: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta 2008; 392:41–45.

Sint T, Donohue JF, Ghio AJ. Ambient air pollution particles and the acute exacerbation of chronic obstructive pulmonary disease. Inhalat Toxicol 2008; 20:25–29.

Tang WHW, Francis GS, Morrow DA, Newby LK, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical utilization of cardiac biomarker testing in heart failure [Review]. Clin Biochem 2008; 41:210–221.

• Viola R, Kiteley C, Lloyd NS, et al. The management of dyspnea in cancer patients: a systematic review. Support Care Cancer 2008; 16:329–337.[15]

Worster A, Balion CM, Hill SA, Santaguida P, et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: A systematic review. Clin Biochem 2008; 41:250–259.

Back to Top | Article Outline

Opioid management/dyspnea

Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med 2008; 11:204–216.

Gauna AA, Kang SK, Triano ML, Swatko ER, et al. Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: An observational case series. J Palliat Med 2008; 11:643–648.

Pattinson KTS. Opioids and the control of respiration [Review]. Br J Anaesth 2008; 100:747–758.

Viola R, Kiteley C, Lloyd NS, Mackay JA, et al. The management of dyspnea in cancer patients: a systematic review [Review]. Support Care Cancer 2008; 16:329–337.

Back to Top | Article Outline

Pain: nonmalignant disease

Facial pain: an update

Review: (pp. 125–130)

• Abrahamsen R, Baad-Hansen L, Svensson P. Hypnosis in the management of persistent idiopathic orofacial pain: clinical and psychosocial findings. Pain 2008; 136:44–52.[53]

• Afari N, Wen Y, Buchwald D, et al. Are posttraumatic stress disorder symptoms and temporomandibular pain associated? Findings from a community-based twin registry. J Orofac Pain 2008; 22:41–49.[23]

• Aggarwal VR, McBeth J, Lunt M, et al. Development and validation of classification criteria for idiopathic orofacial pain for use in population-based studies. J Orofac Pain 2007; 21:203–215.[05]

• Aggarwal VR, McBeth J, Zakrzewska JM, et al. Are reports of mechanical dysfunction in chronic oro-facial pain related to somatisation? A population based study. Eur J Pain 2008; 12:501–507.[11]

Aggarwal VR, McBeth J, Zakrzewska JM, Lunt M, et al. Are reports of mechanical dysfunction in chronic oro-facial pain related to somatisation? A population based study. Eur J Pain 2008; 12:501–507.

• Aggarwal VR, McBeth J, Zakrzewska JM, Macfarlane GJ. Unexplained orofacial pain: is an early diagnosis possible? Br Dent J 2008; 205:E1–E6.[04]

• Al-Jundi MA, John MT, Setz JM, et al. Meta-analysis of treatment need for temporomandibular disorders in adult nonpatients. J Orofac Pain 2008; 22:97–107.[31]

Anand KS, Sharma S. Quality of life in migraine. Drug Dev Res 2007; 68:403–411.

•• Baad-Hansen L. Atypical odontalgia - pathophysiology and clinical management. J Oral Rehabil 2008; 35:1–11.[41]

• Baad-Hansen L, Leijon G, Svensson P, List T. Comparison of clinical findings and psychosocial factors in patients with atypical odontalgia and temporomandibular disorders. J Orofac Pain 2008; 22:7–14.[39]

• Balasubramaniam R, de LR, Zhu H, Nickerson RB, et al. Prevalence of temporomandibular disorders in fibromyalgia and failed back syndrome patients: a blinded prospective comparison study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:204–216.[24]

• Benoliel R, Birman N, Eliav E, Sharav Y. The International Classification of Headache Disorders: accurate diagnosis of orofacial pain? Cephalalgia 2008; 28:752–762.[06]

Benoliel R, Birman N, Eliav E, Sharav Y. The international classification of headache disorders: Accurate diagnosis of orofacial pain? Cephalalgia 2008; 28:752–762.

•• Bergstrom I, List T, Magnusson T. A follow-up study of subjective symptoms of temporomandibular disorders in patients who received acupuncture and/or interocclusal appliance therapy 18–20 years earlier. Acta Odontol Scand 2008; 66:88–92.[19]

• Bertoli E, de LR, Schmidt JE, et al. Prevalence and impact of posttraumatic stress disorder symptoms in patients with masticatory muscle or temporomandibular joint pain: differences and similarities. J Orofac Pain 2007; 21:107–119.[22]

Crampsey DP, Cochrane L, Roebuck D, Hartley BE. Chronic facial pain following injection of sodium tetradecyl sulphate into an intraparotid haemolymphangioma. J Laryngol Otol 2008; 122:1002–1004.

•• Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol 2008; 15:1013–1028.[46]

• De Boever JA, Nilner M, Orthlieb JD, Steenks MH. Recommendations by the EACD for examination, diagnosis, and management of patients with temporomandibular disorders and orofacial pain by the general dental practitioner. J Orofac Pain 2008; 22:268–278.[03]

Drummond PD, Treleaven-Hassard S. Electrical stimulation decreases neuralgic pain after trigeminal deafferentation. Cephalalgia 2008; 28:782–785.

• Eliav E, Kamran B, Schaham R, Czerninski R, et al. Evidence of chorda tympani dysfunction in patients with burning mouth syndrome. J Am Dent Assoc 2007; 138:628–633.[44]

•• Emshoff R, Bosch R, Pumpel E, et al. Low-level laser therapy for treatment of temporomandibular joint pain: a double-blind and placebo-controlled trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105:452–456.[35]

Gameiro GH, Nouer DF, Pereira-Neto JS, Magnani MBBD, et al. Histological analysis of orthodontic root resorption in rats treated with the cyclooxygenase-2 (COX-2) inhibitor celecoxib. Orthod Craniofac Res 2008; 11:156–161.

Garcia-Pola MJ, Garcia-M Aritn JM, Varela-Centelles P, Bilbao-Alonso A, et al. Oral and facial piercing: Associated complications and clinical repercussion [Review]. Quintessence Int 2008; 39:51–59.

Garza I. The trigeminal trophic syndrome: an unusual cause of face pain, dysaesthesias, anaesthesia and skin/soft tissue lesions. Cephalalgia 2008; 28:980–985.

• Glaros AG, Urban D, Locke J. Headache and temporomandibular disorders: evidence for diagnostic and behavioural overlap. Cephalalgia 2007; 27:542–549.[21]

• Glaros AG, Williams K, Lausten L. Diurnal variation in pain reports in temporomandibular disorder patients and control subjects. J Orofac Pain 2008; 22:115–121.[27]

•• Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71:1183–1190.[47]

Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, et al. Efficacy of botulinum toxin in treating myofascial pain in bruxers: A controlled placebo pilot study. Cranio-J Craniomandib Pract 2008; 26:126–135.

Harrison AR, Erickson JP, Anderson JS, Lee MS. Pain relief in patients receiving periocular botulinum toxin A. Ophthal Plast Reconstr Surg 2008; 24:113–116.

Harti DM, Cohen M, Julieron M, Marandas P, et al. Botulinum toxin for radiation-induced facial pain and trismus. Otolaryngol Head Neck Surg 2008; 138:459–463.

• Isong U, Gansky SA, Plesh O. Temporomandibular joint and muscle disorder-type pain in U.S. adults: the National Health Interview Survey. J Orofac Pain 2008; 22:317–322.[17]

Ivkovic N, Mladenovic I, Petkovic S, Stojic D. TMD chronic pain and masseter silent period in psychiatric patients on antidepressive therapy. J Oral Rehabil 2008; 36:424–432.

Kakizawa Y, Seguchi T, Kodama K, Ogiwara T, et al. Anatomical study of the trigeminal and facial cranial nerves with the aid of 3.0-tesla magnetic resonance imaging. J Neurosurg 2008; 108:483–490.

Kashkouli MB, Salimi S, Bakhtiari P, Parvaresh MM, et al. EMLA cream application without occlusive dressing before upper facial botulinum toxin injection - A randomized, double-blind, placebo-controlled trial. Ann Plast Surg 2008; 60:353–356.

Khoo SP, Yap AUJ, Chan YH, Bulgiba AM. Translating the research diagnostic criteria for temporomandibular disorders into Malay: Evaluation of content and process. J Orofacial Pain 2008; 22:131–138.

Kunz M, Mylius V, Schepelmann K, Lautenbacher S. Impact of age on the facial expression of pain. J Psychosom Res 2008; 64:311–318.

• Lemos L, Flores S, Oliveira P, Almeida A. Gabapentin supplemented with ropivacain block of trigger points improves pain control and quality of life in trigeminal neuralgia patients when compared with gabapentin alone. Clin J Pain 2008; 24:64–75.[48]

• List T, Leijon G, Helkimo M, et al. Clinical findings and psychosocial factors in patients with atypical odontalgia: a case-control study. J Orofac Pain 2007; 21:89–98.[38]

Lo Piccolo M, Crestanello J, Yoo SS, Sciubba J, et al. Facial erythema ab igne of rapid onset. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105:E38–E40.

Mannix LK. A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future [Review]. Expert Opin Pharmacother 2008; 9:1001–1011.

Marklund S, Wanman A. Incidence and prevalence of myofascial pain in the jaw-face region. A one-year prospective study on dental students. Acta Odontol Scand 2008; 66:113–121.

McMurray CA, Bajwa ZH. The role of extraocular and facial muscle trigger points in cephalalgia [Review]. Curr Pain Headache Rep 2008; 12:350–354.

• Mulet M, Decker KL, Look JO, et al. A randomized clinical trial assessing the efficacy of adding 6 × 6 exercises to self-care for the treatment of masticatory myofascial pain. J Orofac Pain 2007; 21:318–328.[33]

Nakae A, Nakai K, Tanaka T, Hagihira S, et al. The role of RNA editing of the serotonin 2C receptor in a rat model of oro-facial neuropathic pain. Eur J Neurosci 2008; 27:2373–2379.

Nifosi F, Violato E, Pavan C, Sifari L, et al. Psychopathology and clinical features in an Italian sample of patients with myofascial and temporomandibular joint pain: Preliminary data. Int J Psychiatry Med 2007; 37:283–300.

•• Nilsson IM, List T, Drangsholt M. Incidence and temporal patterns of temporomandibular disorder pain among Swedish adolescents. J Orofac Pain 2007; 21:127–132.[18]

Paoli J, Halldin C, Ericson MB, Wennberg AM. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol 2008; 33:559–564.

• Patton LL, Siegel MA, Benoliel R, De Laat A. Management of burning mouth syndrome: systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103(Suppl); 2007:S13–S39.[42]

• Ritenbaugh C, Hammerschlag R, Calabrese C, et al. A pilot whole systems clinical trial of traditional chinese medicine and naturopathic medicine for the treatment of temporomandibular disorders. J Altern Complement Med 2008; 14:475–487.[37]

Robert C, Caillieux N, Wilson CS, Gaudy JF, et al. World orofacial pain research production: A bibliometric study (2004-2005). J Orofacial Pain 2008; 22:181–189.

Rohatagi S, Kastrissios H, Sasahara K, Truitt K, et al. Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain. Br J Clin Pharmacol 2008; 66:60–70.

Ross ED. Facial expressions, pain and nociception - are they related? Nat Clin Pract Neurol 2008; 4:304–305.

Rossetti LMN, de Araujo CDP, Rossetti PHO, Conti PCR. Association between rhythmic masticatory muscle activity during sleep and masticatory myofascial pain: A polysomnographic study. J Orofacial Pain 2008; 22:190–200.

Ruffatti S, Zanchin G, Maggioni F. A case of intractable facial pain secondary to metastatic lung cancer. Neurol Sci 2008; 29:117–119.

Salomons TV, Coan JA, Hunt SM, Backonja MM, et al. Voluntary facial displays of pain increase suffering in response to nociceptive stimulation. J Pain 2008; 9:443–448.

Sandell T, Eide PK. Effect of microvascular decompression in trigeminal neuralgia patients with or without constant pain. Neurosurgery 2008; 63:93–99.

• Sardella A, Lodi G, Demarosi F, et al. Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. J Oral Pathol Med 2008; 37:395–401.[45]

•• Schwaiger J, Kiechl S, Seppi K, et al. Prevalence of primary headaches and cranial neuralgias in men and women aged 55-94 years (Bruneck Study). Cephalalgia 2009; 29:179–187.[10]

Sethi A, Sethi D, Agarwal AK, Nigam S, et al. Tubercular and chronic pyogenic osteomyelitis of cranio-facial bones: a retrospective analysis. J Laryngol Otol 2008; 122:799–804.

Sipila K, Ylostalo PV, Ek E, Raustia AM. Association of stress level with facial pain: the role of coping. Cranio-J Craniomandib Pract 2008; 26:216–221.

•• Spatz AL, Zakrzewska JM, Kay EJ. Decision analysis of medical and surgical treatments for trigeminal neuralgia: how patient evaluations of benefits and risks affect the utility of treatment decisions. Pain 2007; 131:302–310.[50]

•• Stowell AW, Gatchel RJ, Wildenstein L. Cost-effectiveness of treatments for temporomandibular disorders: biopsychosocial intervention versus treatment as usual. J Am Dent Assoc 2007; 138:202–208.[34]

•• Svensson P, Jadidi F, Arima T, et al. Relationships between craniofacial pain and bruxism. J Oral Rehabil 2008; 35:524–547.[26]

Velasco F, Argulles C, Carrillo-Ruiz JD, Castro G, et al. Efficacy of motor cortex stimulation in the treatment of neuropathic pain: a randomized double-blind trial. J Neurosurg 2008; 108:698–706.

•• Von KM, Dunn KM. Chronic pain reconsidered. Pain -2008; 138:267–276.[13]

Walters H, Lewis E, Wolper R, Yachnis AT, et al. Neurotropic melanoma of the trigeminal nerve: A case of atypical facial pain. J Oral Maxillofac Surg 2008; 66:547–550.

•• Wiese M, Svensson P, Bakke M, et al. Association between temporomandibular joint symptoms, signs, and clinical diagnosis using the RDC/TMD and radiographic findings in temporomandibular joint tomograms. J Orofac Pain 2008; 22:239–251.[29]

• Wiesinger B, Malker H, Englund E, Wanman A. Back pain in relation to musculoskeletal disorders in the jaw-face: a matched case-control study. Pain 2007; 131:311–319.[25]

•• Wolf E, Birgerstam P, Nilner M, Petersson K. Nonspecific chronic orofacial pain: studying patient experiences and perspectives with a qualitative approach. J Orofac Pain 2008; 22:349–358.[16]

Wolfe S, Van Stavern G. Characteristics of patients presenting with ocular pain. Can J Opthalmol-J Can Opthalmol 2008; 43:432–434.

Yozgatian JH, Zeredo JL, Hotokezaka H, Koga Y, et al. Emotional stress- and pain-related behaviors evoked by experimental tooth movement. Angle Orthod 2008; 78:487–494.

•• Zakrzewska JM, Forssell H, Glenny AM. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev 2005;CD002779.[43]

• Zakrzewska JM, Jorns TP, Spatz A. Patient led conferences: who attends, are their expectations met and do they vary in three different countries? Eur J Pain 2008. [Epub ahead of print][51]

Zhang ZJ, Dellon AL. Facial pain and headache associated with brachial plexus compression in the thoracic inlet. Microsurgery 2008; 28:347–350.

Back to Top | Article Outline

Pain research methodology

Arendt-Nielsen L. Translational human pain research. Eur J Pain 2007:38–40.

Asmundson GJG, Bovell CV, Carleton RN, McWilliams LA. The Fear of Pain Questionnaire-Short Form (FPQ-SF): Factorial validity and psychometric properties. Pain 2008; 134:51–58.

Backonja MM, Coe CL, Muller DA, Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol 2008; 195:157–163.

Bernardes SF, Keogh E, Lima ML. Bridging the gap between pain and gender research: A selective literature review [Review]. Eur J Pain 2008; 12:427–440.

Blum K, Chen ALC, Chen TJH, Prihoda TJ, et al. The H-Wave (R) device is an effective and safe meta-non-pharmacological analgesic for chronic pain: a meta-analysis [Review]. Adv Ther 2008; 25:644–657.

Carroll LJ, Eric LH, Cote P, Hogg-Johnson S, et al. Research priorities and methodological implications - The bone and joint decade 2000-2010 task force on neck pain and its associated disorders. Spine 2008; 33:S214–S220.

Carroll LJ, Hurwitz EL, Cote P, Hogg-Johnson S, et al. Research priorities and methodological implications - The bone and joint decade 2000-2010 task force on neck pain and its associated disorders. Eur Spine J 2008; 17:S214–S220.

Castral TC, Warnock F, Leite AM, Haas VJ, et al. The effects of skin-to-skin contact during acute pain in preterm newborns. Eur J Pain 2008; 12:464–471.

Donovan KA, Taliaferro LA, Brock CW, Bazargan S. Sex differences in the adequacy of pain management among patients referred to a multidisciplinary cancer pain clinic. J Pain Symptom Manage 2008; 36:167–172.

Dore-Savard L, Roussy G, Dansereau MA, Collingwood MA, et al. Central delivery of Dicer-substrate siRNA: A direct application for pain research. Mol Ther 2008; 16:1331–1339, 2008 Jul.

Downian R, Rissacher D, Schuckers S. EEG indices of tonic pain-related activity in the somatosensory cortices. Clin Neurophysiol 2008; 119:1201–1212.

Edwards RR, Almeida DM, Klick B, Haythornthwaite JA, et al. Duration of sleep contributes to next-day pain report in the general population. Pain 2008; 137:202–207.

Fan Y, Han SH. Temporal dynamic of neural mechanisms involved in empathy for pain: An event-related brain potential study. Neuropsychologia 2008; 46:160–173.

Farion KJ, Michalowski W, Rubin S, Wilk S, et al. Prospective evaluation of the MET-AP system providing triage plans for acute pediatric abdominal pain. Int J Medical Inform 2008; 77:208–218.

Finley GA, Forgeron P, Arnaout M. Action research: Developing a pediatric cancer pain program in Jordan. J Pain Symptom Manage 2008; 35:447–454.

Gaspardo CM, Miyase CI, Chimello JT, Martinez FE, et al. Is pain relief equally efficacious and free of side effects with repeated doses of oral sucrose in preterm neonates? Pain 2008; 137:16–25.

Hanley MA. Therapeutic touch with preterm infants: Composing a treatment. Explore-J Sci Heal 2008; 4:249–258, 2008 Jul–Aug.

Hans G, Deseure K, Adriaensen H. Endothelin-1-induced pain and hyperalgesia: A review of pathophysiology, clinical manifestations and future therapeutic options [Review]. Neuropeptides 2008; 42:119–132.

Hawker GA, Davis AM, French MR, Cibere J, et al. Development and preliminary psychometric testing of a new OA pain measure - an OARSI/OMERACT initiative. Osteoarth Cartilage 2008; 16:409–414.

Jensen MP, Mardekian J, Lakshminarayanan M, Boye ME. Validity of 24-h recall ratings of pain severity: Biasing effects of “Peak” and “End” pain. Pain 2008; 137:422–427.

Jongudomkarn D, Angsupakorn N, Siripul P. The development and validation of the Khon Kaen University Pediatric Pain Assessment Tool for school-aged Isaan children in Thailand. J Transcult Nurs 2008; 19:213–222.

Jordan A, Eccleston C, McCracken LM, Connell H, et al. The Bath Adolescent Pain - Parental Impact Questionnaire (BAP-PIQ): Development and preliminary psychometric evaluation of an instrument to assess the impact of parenting an adolescent with chronic pain. Pain 2008; 137:478–487.

Jordan KP, Croft P. Opportunities and limitations of general practice databases in pain research. Pain 2008; 137:469–470.

Khorsan R, Coulter ID, Hawk C, Choate CG. Measures in chiropractic research: Choosing patient-based outcome assessments [Review]. J Manipulative Physiol Ther 2008; 31:355–375.

Kuziemsky CE, Weber-Jahnke JH, Lau F, Downing GM. An interdisciplinary computer-based information tool for palliative severe pain management. J Am Med Informatics Assoc 2008; 15:374–382.

Langley CK, Aziz Q, Bountra C, Gordon N, et al. Volunteer studies in pain research - Opportunities and challenges to replace animal experiments - The report and recommendations of a Focus on Alternatives workshop [Review]. Neuroimage 2008; 42:467–473.

Lewkowski MD, Young SN, Ghosh S, Ditto B. Effects of opioid blockade on the modulation of pain and mood by sweet taste and blood pressure in young adults. Pain 2008; 135:75–81.

Logan DE, Claar RL, Scharff L. Social desirability response bias and self-report of psychological distress in pediatric chronic pain patients. Pain 2008; 136:366–372.

MacLaren J, Kain ZN. Research to practice in pediatric pain: What are we missing? Pediatrics 2008; 122:443–444.

Max MB, Stewart WF. The molecular epidemiology of pain: a new discipline for drug discovery [Review]. Nat Rev Microbiol 2008; 7(8):647-658, 200:647–658.

McGrath PJ, Walco GA, Turk DC, Dworkin RH, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain 2008; 9:771–783.

Nicholas MK, Asghari A, Blyth FM. What do the numbers mean? Normative data in chronic pain measures. Pain 2008; 134:158–173.

Niederberger E, Geisslinger G. Proteomics in Neuropathic pain research [Review]. Anesthesiology 2008; 108:314–323.

Novak S, Nemeth WC. The basis for recommending repeating epidural steroid injections for radicular low back pain: A literature review [Review]. Arch Phys Med Rehabil 2008; 89:543–552.

Rusu AC, Hasenbring M. Multidimensional Pain Inventory derived classifications of chronic pain: Evidence for maladaptive pain-related coping within the dysfunctional group. Pain 2008; 134:80–90.

Shega JW, Rudy T, Keefe FJ, Perri LC, et al. Validity of pain behaviors in persons with mild to moderate cognitive impairment. J Am Geriatr Soc 2008; 56:1631–1637.

Simon D, Craig KD, Gosselin F, Belin P, et al. Recognition and discrimination of prototypical dynamic expressions of pain and emotions. Pain 2008; 135:55–64.

Slater R, Cantarella A, Franck L, Meek J, et al. How well do clinical pain assessment tools reflect pain in infants? - art. no. e129. PLoS Med 2008; 5:928–933.

Sullivan MJL. Toward a biopsychomotor conceptualization of pain - Implications for research and intervention. Clin J Pain 2008; 24:281–290.

Tanabe M, Takasu K, Yamaguchi S, Kodama D, et al. Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment. Anesthesiology 2008; 108:929–937.

Terry RH, Niven CA, Brodie EE, Jones RB, et al. Memory for pain? A comparison of nonexperiential estimates and patients' reports of the quality and intensity of postoperative pain. J Pain 2008; 9:342–349.

Thompson T, Keogh E, French CC, Davis R. Anxiety sensitivity and pain: Generalis ability across noxious stimuli. Pain 2008; 134:187–196.

Treede RD, Jensen TS, Campbell JN, Cruccu G, et al. Neuropathic pain - Redefinition and a grading system for clinical and research purposes [Review]. Neurology 2008; 70:1630–1635.

Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine [Review]. Int Clin Psychopharmacol 2008; 23:161–169.

Uyan ZS, Bilgen H, Topuzoglu A, Akman I, et al. Comparison of three neonatal pain scales during minor painful procedures. J Matern Fetal Neonatal Med 2008; 21:305–308.

Vit JP, Ohara PT, Bhargava A, Kelley K, et al. Silencing the kir4.1 potassium channel subunit in satellite glial cells of the rat trigeminal ganglion results in pain-like behavior in the absence of nerve injury. J Neurosci 2008; 28:4161–4171.

Watkins EA, Wollan PC, Melton LJ, Yawn BP. A population in pain: Report from the Olmsted County Health Study. Pain Medicine 2008; 9:166–174.

Back to Top | Article Outline

Qualitative research on pain

Review: (pp. 131–135)

Adams J, Broom A, Jennaway M. Qualitative methods in chiropractic research: One framework for future inquiry. J Manipulative Physiol Ther 2008; 31:455–460.

Bender JL, Hohenadel J, Wong J, Katz J, et al. What patients with cancer want to know about pain: A qualitative study. J Pain Symptom Manage 2008; 35:177–187.

• Blomberg A-M, Hylander I, Tőrnkvist L. District nurses' involvement in pain care: a theoretical model. J Clin Nurs 2008; 17:2022–2031.[05]

•• Campbell C, Cramb G. ‘Nobody likes a back bore’: exploring lay perspectives of chronic pain: Revealing the hidden voice of nonservice users. Scand J Caring Sci 2008; 22:383–390.[11]

• Carnes D, Anwer Y, Underwood M, et al. Influences on older people's decision making regarding choice of topical or oral NSAIDS for knee pain: qualitative study. Br Med J 2008; 336:142–145.[15]

Conboy L, Quilty MT, Kerr C, Shaw J, et al. A qualitative analysis of adolescents' experiences of active and sham Japanese-style acupuncture protocols administered in a clinical trial. J Altern Complement Med 2008; 14:699–705.

•• Cooper K, Smith BH, Hancock E. Patient-centredness in physiotherapy from the perspective of the chronic low back pain patient. Physiotherapy 2008; 94:244–252.[20]

Davis PJC, Williams HJ. The investigation and management of back pain in children. Arch Dis Childhood-Educ Pract Ed 2008; 93:73–83.

• Evans S, de Souza L. Dealing with chronic pain: giving voice to the experiences of mothers with chronic pain and their children. Qual Health Res 2008; 18:489–500.[16]

Goubert L, Vervoort T, Sullivan MJL, Verhoeven K, et al. Parental emotional responses to their child's pain: The role of dispositional empathy and catastrophizing about their child's pain. J Pain 2008; 9:272–279.

He Q, Luo X, Jin W, Huang Y, et al. Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. Oncogene 2008; 27:2656–2660.

Hechler T, Kosfelder J, Denecke H, Dobe M, et al. Pain-related coping strategies in children and adolescents with chronic pain. Validation of a German version of the Paediatric Pain Coping Inventory (PPCI revised) [German]. Schmerz 2008; 22:442–457.

Hurley RW, Adams MCB. Sex, gender, and pain: An over-view of a complex field [Review]. Anesth Analg 2008; 107:309–317.

Jacob E, Mueller BU. Pain experience of children with sickle cell disease who had prolonged hospitalizations for acute painful episodes. Pain Medicine 2008; 9:13–21.

Khorsan R, Coulter ID, Hawk C, Choate CG. Measures in chiropractic research: Choosing patient-based outcome assessments [Review]. J Manipulative Physiol Ther 2008; 31:355–375.

Koffman J, Morgan M, Edmonds P, Speck P, et al. Cultural meanings of pain: a qualitative study of Black Caribbean and White British patients with advanced cancer. Palliative Med 2008; 22:350–359.

Logan DE, Claar RL, Scharff L. Social desirability response bias and self-report of psychological distress in pediatric chronic pain patients. Pain 2008; 136:366–372.

MacLaren J, Kain ZN. Research to practice in pediatric pain: What are we missing? Pediatrics 2008; 122:443–444.

Nilsson S, Finnstrom B, Kokinsky E. The FLACC behavioral scale for procedural pain assessment in children aged 5-16 years. Pediatr Anesth 2008; 18:767–774.

Patel S, Peacock SM, McKinley RK, Carter DC, et al. GPs' experience of managing chronic pain in a South Asian community - a qualitative study of the consultation process. Fam Pract 2008; 25:71–77.

• Patel S, Peacock SM, McKinley RK, et al. GP's experience of managing chronic pain in a South Asian community: a qualitative study of the consultation process. Fam Pract 2008; 25:71–77.[06]

Rusu AC, Hasenbring M. Multidimensional Pain Inventory derived classifications of chronic pain: Evidence for maladaptive pain-related coping within the dysfunctional group. Pain 2008; 134:80–90.

•• Sim J, Madden S. Illness experience in fibromyalgia syndrome: a metasynthesis of qualitative studies. Soc Sci Med 2008; 67:57–67.[27]

Simon D, Craig KD, Gosselin F, Belin P, et al. Recognition and discrimination of prototypical dynamic expressions of pain and emotions. Pain 2008; 135:55–64.

Sullivan MJL. Toward a biopsychomotor conceptualization of pain - Implications for research and intervention. Clin J Pain 2008; 24:281–290.

Sumitani M, Miyauchi S, McCabe CS, Shibata M, et al. Mirror visual feedback alleviates deafferentation pain, depending on qualitative aspects of the pain: a preliminary report. Rheumatology 2008; 47:1038–1043.

van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis CGB, et al. Main problems experienced by children with epidermolysis bullosa: A qualitative study with semi-structured interviews. Acta Derm Venereol (Stockh) 2008; 88:143–150.

Veehof MM, Taal E, Willems MJ, Van De Laar MAFJ. Determinants of the use of wrist working splints in rheumatoid arthritis. Arthritis Rheum 2008; 59:531–536.

Vervoort T, Craig KD, Goubert L, Dehoorne J, et al. Expressive dimensions of pain catastrophizing: A comparative analysis of school children and children with clinical pain. Pain 2008; 134:59–68.

Walker SM. Pain in children: recent advances and ongoing challenges. Br J Anaesth 2008; 101:101–110.

•• Wolfe BJ, Sirois FM. Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation 2008; 17: 877–886.[24]

Woodgate RL. Feeling states - A new approach to understanding how children and adolescents with cancer experience symptoms. Cancer Nurs 2008; 31:229–238.

Back to Top | Article Outline

COX inhibitors: an update

Akula KK, Dhir A, Kulkarni SK. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: Possible involvement of adenosinergic mechanism. Epilepsy Res 2008; 78:60–70.

Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: Point. Cancer Epidemiol Biomarkers Prev 2008; 17.

Arunasree KM, Roy KR, Anilkumar K, Aparna A, et al. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: Role of COX-2 and MDR-1. Leuk Res 2008; 32:855–864.

Badriyyah M, Mazeh H, Brocke S, Osmanova V, et al. Prevention of lipopolysaccharide-induced intussusception in mice by the COX2 inhibitor rofecoxib. Pediatr Surg Int 2008; 24:333–336.

Chen LK, He YJ, Huang H, Liao H, et al. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Med Oncol 2008; 25:161–171.

Cunnington M, Webb D, Qizilbash N, Blum D, et al. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiology and Drug Safety 2008; 17:601–608.

Devigili G, Tugnoli V, Penza P, Camozzi F, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008; 131:1912–1925.

Dogne JM, Thiry A, Supuran CT. Carbonic anhydrase inhibition: Insight into non-COX-2 pharmacological effect of some coxibs [Review]. Curr Pharm Design 2008; 14:679–684.

Farooq M, Haq I, Qureshi AS. Cardiovascular risks of COX inhibition: current perspectives [Review]. Expert Opin Pharmacother 2008; 9:1311–1319.

Flier S, Buhre W. Selective COX-2 inhibitors: New insights into mechanisms of side effects? Crit Care Med 2008; 36:2694–2695.

Gadad AK, Palkar MB, Arland K, Noolvi MN, et al. Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: A novel class of cyclooxygenase-2 inhibitors. Bioorg Med Chem 2008; 16:276–283.

Germann B, Neuhaus W, Hofer-Warbinek R, Noe CR. Applying blood-brain barrier in vitro models to study the influence of drugs on endothelial cells - effects of selected COX-inhibitors. Pharmazie 2008; 63:303–307.

Gierse J, Nickols M, Leahy K, Warner J, et al. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur J Pharmacol 2008; 588:93–98.

Gupta AK, Gupta RA, Soni LK, Kaskhedikar SG. Exploration of physicochemical properties and molecular modelling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors. Eur J Med Chem 2008; 43:1297–1303.

Hagar W, Vichinsky E. Advances in clinical research in sickle cell disease. Br J Haematol 2008; 141:346–356.

Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors - art. no. 237. BMC Cancer 2008:237.

Hau P, Kunz-Schughart L, Bogdahn U, Baumgart U, et al. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-Gamma Agonists in recurrent high-grade gliomas - A phase II study. Oncology (Williston Park) 2007:21–25.

Hennekens CH, Borzak S. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther 2008; 13:41–50.

Hinz B, Brune K. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology [Review]. Trends Pharmacol Sci 2008; 29:391–397.

Kowalski KG, Olson S, Remmers AE, Hutmacher MM. Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. Clin Pharmacol Ther 2008; 83:857–866.

Layton D, Souverein PC, Heerdink ER, Shakir SAW, et al. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users - A cohort study using pharmacy dispensing data in the Netherlands. Drug Safety 2008; 31:143–158.

Li W, Zhang HH, Xu RJ, Zhuo GC, et al. Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo. Med Oncol 2008; 25:172–177.

Lin SJ, Tsai WJ, Chiou WF, Yang TH, et al. Selective COX-2 inhibitors. Part 2: Synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem 2008; 16:2697–2706.

Matsumoto MA, De Oliveira A, Ribeiro PD, Nary H, et al. Short-term administration of non-selective and selective cox-2 nsaids do not interfere with bone repair in rats. J Mol Histol 2008; 39:381–387.

McGettigan P, Han P, Jones L, Whitaker D, et al. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol 2008; 65:927–934.

Mukawa K, Fujii S, Tominaga K, Yoshitake N, et al. Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium. Oncol Rep 2008; 19:393–399.

Okumura T, Sakakibara A, Murata Y, Kita Y. Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. Eur J Pharmacol 2008; 578:97–99.

Orjales A, Mosquera R, Lopez B, Olivera R, et al. Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Bioorg Med Chem 2008; 16:2183–2199.

Pan MH, Chang YH, Tsai ML, Lai CS, et al. Pterostilbene suppressed lipopolysaccharide-induced up-expression of MOS and COX-2 in murine macrophages. J Agricultural Food Chem 2008; 56:7502–7509.

Reddy MVR, Billa VK, Pallela VR, Mallireddigari MR, et al. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl) 3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitor. Bioorg Med Chem 2008; 16:3907–3916.

Rohatagi S, Kastrissios H, Sasahara K, Truitt K, et al. Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain. Br J Clin Pharmacol 2008; 66:60–70.

Roumie CL, Mitchel EF, Kaltenbach L, Arbogast PG, et al. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39:2037–2045.

Ruschitzka F, Zhang J, Ding EL, Song Y. Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension. Curr Hypertens Rep 2007; 9:41–44.

Sakya SM, Shavnya A, Cheng H, Li C, et al. Comparative structure-activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition. Bioorg Med Chem Lett 2008; 18:1042–1045.

Scholz M, Ulbrich HK, Dannhardt G. Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem 2008; 43:1152–1159.

Schonthal AH, Chen TC, Hofman FM, Louie SG, et al. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs [Review]. Expert Opin Investig Drugs 2008; 17:197–208.

Selg E, Lastbom L, Ryrfeldt A, Kumlin M, et al. Effects of selective and non-selective COX inhibitors on antigen-induced release of prostanoid mediators and bronchoconstriction in the isolated perfused and ventilated guinea pig lung. Prostaglandins Leukot Essent Fatty Acids 2008; 78:89–97.

Setakis E, Leufkens HGM, van Staa TP. Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis Rheum 2008; 59:1105–1111.

Shi SJ, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors [Review]. Eur J Clin Pharmacol 2008; 64:233–252.

Silakari P, Shrivastava SD, Silakari G, Kohli DV, et al. QSAR analysis of 1,3-diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives as selective COX-2 inhibitors. Eur J Med Chem 2008; 43:1559–1569.

Singh P, Mittal A, Bhardwaj A, Kaur S, et al. 1-Toluene-sulfonyl-3-[(3 '-hydroxy-5 '-substituted)-gamma-butyrolactone]-indoles: Synthesis, COX-2 inhibition and anti-cancer activities. Bioorg Med Chem Lett 2008; 18:85–89.

Singh P, Mittal A, Kaur S, Holzer W, et al. 2,3-Diaryl-5-ethylsulfanylmethyltetrahydrofurans as a new class of COX-2 inhibitors and cytotoxic agents. Org Biomol Chem 2008; 6:2706–2712.

Sud'ina GF, Pushkareva MA, Shephard P, Klein T. Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors. Prostaglandins Leukot Essent Fatty Acids 2008; 78:99–108.

Sukel MPP, van der Linden MW, Chen C, Erkens JA, et al. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiology and Drug Safety 2008; 17:9–19.

Tavolari S, Bonafe M, Marini M, Ferreri C, et al. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 2008; 29:371–380.

Toomey D, Conroy H, Jarnicki AG, Higgins SC, et al. Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. Vaccine 2008; 26:3540–3549.

Ushiyama S, Yamada T, Murakami Y, Kumakura SI, et al. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. Eur J Pharmacol 2008; 578:76–86.

van Staa TP, Smeeth L, Persson I, Parkinson J, et al. What is the harm-benefit ratio of Cox-2 inhibitors? Int J Epidemiol 2008; 37:405–413.

Wang PH, Cheng MH, Lee WL. The choice of tocolytic drugs for preterm labor-comparison of COX-2 inhibitor and magnesium sulfate. J Obstet Gynaecol Res 2008; 34:439–440.

Wang X, Colby JKL, Yang P, Fischer SM, et al. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue. Carcinogenesis 2008; 29:120–128.

Wang XM, Hamza M, Gordon SM, Wahl SM, et al. COX inhibitors downregulate PDE4D expression in a clinical model of inflammatory pain. Clin Pharmacol Ther 2008; 84:39–42.

Weder AB, Zhang J, El l, Song Y. COX-2 inhibitors and hypertension. Curr Hypertens Rep 2007; 9:3–4.

Yu J, Wu CW, Chu ESH, Hui AY, et al. Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. Biochem Biophys Res Commun 2008; 372:571–577.

Zarghi A, Kakhgi S, Hadipoor A, Daraee B, et al. Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett 2008; 18:1336–1339.

Zhang B, Wang CL, Zhao WH, Lv M, et al. Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World J Gastroenterol 2008; 14:2494–2500.

Zhang H, Ye YJ, Bai ZG, Wang S. The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway. Dig Dis Sci 2008; 53:2195–2203.

Zhao BX, Zhang L, Zhu XS, Wan MS, et al. Synthesis and discovery of a novel pyrazole derivative as an inhibitor of apoptosis through modulating integrin beta 4, ROS, and p53 levels in vascular endothelial cells. Bioorg Med Chem 2008; 16:5171–5180.

Back to Top | Article Outline

Management of acute and chronic pain in sickle cell disease

Barakat LP, Patterson CA, Daniel LC, Dampier C. Quality of life among adolescents with sickle cell disease: mediation of pain by internalizing symptoms and parenting stress - art. no. 60. Health Qual Life Outcomes 2008:60.

Barakat LP, Simon K, Schwartz LA, Radclifif J. Correlates of pain-rating concordance for adolescents with sickle cell disease and their caregivers. Clin J Pain 2008; 24:438–446.

Benza RL. Pulmonary hypertension associated with sickle cell disease: Pathophysiology and rationale for treatment. Lung 2008; 186:247–254.

Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future [Review]. Bone Marrow Transplant 2008; 41:109–117.

da Fonseca MA, Oueis HS, Casannassimo PS. Sickle cell anemia: A review for the pediatric dentist [Review]. Pediatr Dent 2007; 29:159–169.

Darbari DS, Castro O, Taylor JG, Fasano R, et al. Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc 2008; 100:948–951.

Davila HH, Parker J, Webster JC, Lockhart JL, et al. Subarachnoid hemorrhage as complication of phenylephrine injection for the treatment of ischemic priapism in a sickle cell disease patient. J Sex Med 2008; 5:1025–1028.

Fawibe AE. Managing acute chest syndrome of sickle cell disease in an African setting [Review]. Trans R Soc Trop Med Hyg 2008; 102:526–531.

Finkelstein Y, Schechter T, Garcia-Bournissen F, Kirby M, et al. Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study. Clin Ther 2007; 29:2738–2743.

Frei-Jones MJ, Baxter AL, Rogers ZR, Buchanan GR. Vaso-occlusive episodes in older children with sickle cell disease: Emergency department management and pain assessment. J Pediatr 2008; 152:281–285.

Geller AK, O'Connor MK. The sickle cell crisis: A dilemma in pain relief. Mayo Clin Proc 2008; 83:320–323.

Howland MA, Goldfrank LR. Why meperidine should not make a comeback in treating patients with sickle cell disease. Ann Emerg Med 2008; 51:203–205.

Inati A, Koussa S, Taher A, Perrine S. Sickle cell disease: New insights into pathophysiology and treatment. Pediatr Ann 2008; 37:311–321.

Jacob E, Mueller BU. Pain experience of children with sickle cell disease who had prolonged hospitalizations for acute painful episodes. Pain Medicine 2008; 9:13–21.

Kumar DS, Yadavali RP, Concepcion LA, Aniq H. Acute chest pain in a young woman with a chronic illness. Br J Radiol 2008; 81:261–263.

Lettre G, Sankaran VG, Bezerra MAC, Araujo AS, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 2008; 105:11869–11874.

Levenson JL, McClish DK, Dahman BA, Bovbjerg VE, et al. Depression and anxiety in adults with sickle cell disease: The PiSCES project. Psychosom Med 2008; 70:192–196.

Morgan MT. Use of meperidine as the analgesic of choice in treating pain from acute painful sickle cell crisis. Ann Emerg Med 2008; 51:202–203.

Palermo TM, Riley CA, Mitchell BA. Daily functioning and quality of life in children with sickle cell disease pain: Relationship with family and neighborhood socioeconomic distress. J Pain 2008; 9:833–840.

Panepinto JA. Health-related quality of life in sickle cell disease [Review]. Pediatric Blood Cancer 2008; 51:5–9.

Raphael JL, Kamdar A, Beavers MB, Mahoney DH, et al. Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital. Pediatric Blood Cancer 2008; 51:82–85.

Raphael JL, Kamdar A, Wang T, Liu H, et al. Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatric Blood Cancer 2008; 51:398–401.

Shord SS, Chew L, Villan J. Evaluation of oploid induced nausea and vomiting in sickle cell disease. Am J Hematol 2008; 83:196–199.

Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008; 148:94–101.

Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood 2008; 111:997–1003.

Strouse JJ, Takemoto CM, Keefer JR, Kato GJ, et al. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatric Blood Cancer 2008; 50:1006–1012.

Strunk RC, Brown MS, Boyd JH, Bates P, et al. Methacholine challenge in children with sickle cell disease: A case series. Pediatr Pulmonol 2008; 43:924–929.

van Beers EJ, van Tuijn CFJ, MacGillavry MR, van der Giessen A, et al. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica 2008; 93:757–760.

Wiegell SR, Skiveren J, Philipsen PA, Wulf HC. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol 2008; 158:727–733.

Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: A state of nitric oxide resistance [Review]. Free Radic Biol Med 2008; 44:1506–1528.

Zempsky WT, Loiselle KA, Mckay K, Blake GL, et al. Retrospective evaluation of pain assessment and treatment for acute vasoocclusive episodes in children with sickle cell disease. Pediatric Blood Cancer 2008; 51:265–268.

Back to Top | Article Outline

Advances in the management of diabetic peripheral neuropathy

Review: (pp. 136–143)

Actis RL, Ventura LB, Lott DJ, Smith KE, et al. Multi-plug insole design to reduce peak plantar pressure on the diabetic foot during walking. Med Biol Eng Comput 2008; 46:363–371.

Allen SC. Neuropathic pain - The case for opioid therapy. Oncology (Williston Park) 2008:76–82.

Attal N. Drug treatment for neuropathic pain [French]. Presse Med 2008; 37:346–353.

Aurilio C, Pota V, Pace MC, Passavanti MB, et al. Ionic channels and neuropathic pain: Phisiopatology and applications [Review]. J Cell Physiol 2008; 215:8–14.

Baastrup C, Finnerup NB. Pharmacological management of neuropathic pain following spinal cord injury [Review]. CNS Drugs 2008; 22:455–475.

Beard SM, McCrink L, Le TK, Garcia-Cebrian A, et al. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin 2008; 24:385–399.

Cu XP, Li BY, Gao HQ, Wei N, et al. Effects of grape seed proanthocyanidin extracts on peripheral nerves in streptozocin-induced diabetic rats. J Nutr Sci Vitaminol (Tokyo) 2008; 54:321–328.

Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Medicine 2008; 9:253–257.

Dieleman JP, Kerklaan J, Huygen FJPM, Bouma PAD, et al. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008; 137:681–688.

Dray A. Neuropathic pain: emerging treatments. Br J Anaesth 2008; 101:48–58.

Fishbain DA, Lewis JE, Cutler R, Cole B, et al. Can the neuropathic pain scale discriminate between non-neuropathic and neuropathic pain? Pain Medicine 2008; 9:149–160.

• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety and tolerability of pregabalin treatment of painful diabetic peripheral neuropathy: findings from 7 randomized, controlled trials across a range of doses. Diab Care 2008; 31:1448–1454.[37]

Gao Y, Xu CS, Liang SD, Zhang AX, et al. Effect of tetramethylpyrazine on primary afferent transmission mediated by P2X(3) receptor in neuropathic pain states. Brain Res Bull 2008; 77:27–32.

Gilron I. Optimizing neuropathic pain pharmacotherapy: add on or switch over? Nat Clin Pract Neurol 2008; 4:414–415.

Grice GR, Mertens MK. Gabapentin as a potential option for treatment of sciatica. Pharmacotherapy 2008; 28:397–402.

Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: A descriptive study, 2002-2005 - art. no. 26. BMC Fam Pract 2008:26.

Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008; 12:804–813.

Inoue K. Translational research for drugs against the neuropathic pain: Eco-pharma [Japanese]. Yakugaku Zasshi-J Pharm Soc Jpn 2008; 128:59–60.

Jimenez-Andrade GY, Reyes-Garcia G, Sereno G, Ceballos-Reyes G, et al. Pyritinol reduces nociception and oxidative stress in diabetic rats. Eur J Pharmacol 2008; 590:170–176.

Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain - Relationship to study characteristics. Neurology 2008; 70:263–272.

Kiefer RT, Rohr P, Ploppa A, Nohe B, et al. A pilot open-label study of the efficacy of subanesthetic isomeric s(+)-ketamine in refractory CRPS patients. Pain Medicine 2008; 9:44–54.

Kim HJ, Chung JI, Lee SH, Jung YS, et al. Involvement of endogenous prostaglandin F-2 alpha on kainic acid-induced seizure activity through FP receptor: The mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res 2008:153–161.

Klassen A, Di Iorio B, Guastaferro P, Bahner U, et al. High-tone external muscle stimulation in end-stage renal disease: Effects an symptomatic diabetic and uremic peripheral neuropathy. J Renal Nutr 2008; 18:46–51.

Koike H, Iijima M, Mori K, Yamamoto M, et al. Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndrome. J Neurol Neurosurg Psychiatry 2008; 79.

Kuhad A, Sharma S, Chopra K. Lycopene attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pain 2008; 12:624–632.

Lacosamide decreases diabetic neuropathic pain. Formulary 2008; 43:220–.

Lauria G. Controverse - Recent developments in the management of peripheral neuropathy using skin biopsy [French]. Rev Neurol (Paris) 2007; 163:1266–1270.

Loseth S, Stalberg E, Jorde R, Mellgren SI. Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies. J Neurol 2008; 255:1197–1202.

Mariconti P, Collini R. Tramadol SR in arthrosic and neuropathic pain. Minerva Anestesiol 2008; 74:63–68.

Matsuzawa-Yanagida K, Narita M, Nakajima M, Kuzumaki N, et al. Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology 2008; 33:1952–1965.

Mensah-Nyagan AG, Saredi S, Schaeffer V, Kibaly C, et al. Assessment of neuroactive steroid formation in diabetic rat spinal cord using high-performance liquid chromatography and continuous flow scintillation detection [Review]. Neurochem Int 2008; 52:554–559.

Mittlmeier T, Klaue K, Haar P, Beck M. Charcot foot. Current situation and outlook [German]. Unfallchirurg 2008; 111:218–231.

Morgado C, Pinto-Ribeiro F, Tavares I. Diabetes affects the expression of GABA and potassium chloride cotransporter in the spinal cord: A study in streptozotocin diabetic rats. Neurosci Lett 2008; 438:102–106.

Moulin DE. Opioid analgesics in the management of neuropathic pain. Eur J Pain 2007:57–60.

Niederberger E, Geisslinger G. Proteomics in Neuropathic pain research [Review]. Anesthesiology 2008; 108:314–323.

Nieto FR, Entrena JM, Cendan CM, Del Pozo E, et al. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 2008; 137:520–531.

Obrosova IG, Xu WZ, Lyzogubov VV, Ilnytska O, et al. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 2008; 44:972–981.

Olarte JMN. Oxycodone and the challenge of neuropathic cancer pain: A review. Oncology (Williston Park) 2008:83–90.

Ortiz A, Oliveira JP, Waldek S, Warnock DG, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008; 23:1600–1607.

Ozcan M, Ayar A, Canpolat S, Kutlu S. Antinociceptive efficacy of levetiracetam in a mice model for painful diabetic neuropathy. Acta Anaesthesiol Scand 2008; 52:926–930.

Pabbidi RM, Yu SQ, Peng S, Khardori R, et al. Influence of TRPVI on diabetes-induced alterations in thermal pain sensitivity - art. no. 9. Mol Pain 2008:9.

Pacher P. Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: A commentary on “PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy”. Free Radic Biol Med 2008; 44:969–971.

Quattrini C, Jeziorska M, Tavakoli M, Begum P, et al. The Neuropad test: a visual indicator test for human diabetic neuropathy. Diabetologia 2008; 51:1046–1050.

Rao RD, Flynn PJ, Sloan JA, Wong GY, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy - A phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008; 112:2802–2808.

Schmid U, Stopper H, Heidland A, Schupp N. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes-Metab Res Rev 2008; 24:371–377.

Sharma SS, Kumar A, Kaundal RK. Protective effects of 4-aminol,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci 2008; 82:570–576.

Sorensen L, Siddall PJ, Trenell MI, Yue DK. Differences in metabolites in pain-processing brain regions in patients with diabetes and painful neuropathy. Diabetes Care 2008; 31:980–981.

Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review [Review]. Br J Clin Pharmacol 2008; 66:266–275.

Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials - art. no. 29. BMC Neurol 2008:29.

Suzuki T, Ueta K, Tamagaki S, Mashimo T. Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth Analg 2008; 106:1309–1315.

Tanabe M, Murakami T, Ono H. Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy. Journal of Pharmacological Sciences 2008; 107:213–220.

Tolle T, Freynhagen R, Versavel M, Trostmann U, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, double-blind study. Eur J Pain 2008; 12:203–213.

Treede RD, Jensen TS, Campbell JN, Cruccu G, et al. Neuropathic pain - Redefinition and a grading system for clinical and research purposes [Review]. Neurology 2008; 70:1630–1635.

Tsuda M, Ueno H, Kataoka A, Tozakif-Saitoh H, et al. Activation of Dorsal Horn Microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia 2008; 56:378–386.

Tzellos TG, Papazisis G, Amaniti E, Kouvelas D. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature [Review]. Eur J Clin Pharmacol 2008; 64:851–858.

Uceyler N, Sommer C. Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett 2008; 437:194–198.

Velasco F, Argulles C, Carrillo-Ruiz JD, Castro G, et al. Efficacy of motor cortex stimulation in the treatment of neuropathic pain: a randomized double-blind trial. J Neurosurg 2008; 108:698–706.

Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options [Review]. Pain Medicine 2008; 9:660–674.

Vlckova-Moravcova E, Bednarik J, Belobradkova J, Sommer C. Small-fibre involvement in diabetic patients with neuropathic foot pain. Diabet Med 2008; 25:692–699.

Weintraub MI, Cole SP. A randomized controlled trial of the effects of a combination of static and dynamic magnetic fields on carpal tunnel syndrome. Pain Medicine 2008; 9:493–504.

Williams J, Haller VL, Stevens DL, Welch SP. Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol 2008; 584:78–86.

Wohlreich MM, Acharya N, Strombom I, Kuritzky L, et al. Answers to the most common questions about the hepatic safety profile of duloxetine. Postgrad Med 2008; 120:111–118.

Xiao WH, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Medicine 2008; 9:505–517.

Zeng Q, Wang SX, Lim GW, Yang LL, et al. Exacerbated mechanical allodynia in rats with depression-like behavior [Review]. Brain Res 2008:27–38.

Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes-Metab Res Rev 2008; 24:S52–S57.

Back to Top | Article Outline

Management non-malignant pain including surgical/anaesthetic techniques

Arle JE, Shils JL. Motor cortex stimulation for pain and movement disorders. Neurotherapeutics 2008; 5:37–49.

Baastrup C, Finnerup NB. Pharmacological management of neuropathic pain following spinal cord injury [Review]. CNS Drugs 2008; 22:455–475.

Backonja MM, Coe CL, Muller DA, Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol 2008; 195:157–163.

Chang V, Gonzalez P, Akuthota V. Evidence-informed management of chronic low back pain with adjunctive analgesics [Review]. Spine Journal 2008; 8:21–27, 2008 Jan–Feb.

Dufton LM, Konik BB, Colletti R, Stanger C, et al. Effects of stress on pain threshold and tolerance in children with recurrent abdominal pain. Pain 2008; 136:38–43.

Ersek M, Turner JA, Cain KC, Kemp CA. Results of a randomized controlled trial to examine the efficacy of a chronic pain self-management group for older adults [ISRCTN11899548]. Pain 2008; 138:29–40.

Freynhagen R, Rolke R, Baron R, Tolle TR, et al. Pseudoradicular and radicular low-back pain - A disease continuum rather than different entities? Answers from quantitative sensory testing. Pain 2008; 135:65–74.

Girouard K, Harrison MB, Van Den Kerkof E. The symptom of pain with pressure ulcers: A review of the literature [Review]. Ostomy Wound Manag 2008; 54:30–.

Goebel A, Lawson A, Allen S, Glynn C. Buprenorphine injection to the stellate ganglion in the treatment of upper body chronic pain syndromes. Eur J Pain 2008; 12:266–274.

Haefeli M, Elfering A, Aebi M, Freeman BJC, et al. What comprises a good outcome in spinal surgery? A preliminary survey among spine surgeons of the SSE and European spine patients. Eur Spine J 2008; 17:104–116.

Harden RN. Chronic pain and opiates: a call for moderation [Review]. Arch Phys Med Rehabil 2008; 89:S72–S76.

Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth 2008; 101:59–68.

Kamaleri Y, Natvig B, Ihlebaek CM, Bruusgaard D. Localized or widespread musculoskeletal pain: Does it matter? Pain 2008; 138:41–46.

Kanpolat Y, Tuna H, Bo Aurt M, Elhan AH. Spinal and nucleus caudalis dorsal root entry zone operations for chronic pain. Neurosurgery 2008; 63:235–242.

Leeuw M, Goossens MEJB, van Breukelen GJP, de Jong JR, et al. Exposure in vivo versus operant graded activity in chronic low back pain patients: Results of a randomized controlled trial. Pain 2008; 138:192–207.

Lima MC, Fregni F. Motor cortex stimulation for chronic pain - Systematic review and meta-analysis of the literature [Review]. Neurology 2008; 70:2329–2337.

Lynch ME. The pharmacotherapy of chronic pain. Rheum Dis Clin North Am 2008; 34:369–385.

MacPherscon H, Thomas K. Self-help advice as a process integral to traditional acupuncture care: Implications for trial design. Complement Ther Med 2008; 16:101–106.

Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth 2008; 101:77–86.

Memeo A, Loiero M. Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc - A randomized, double-blind, comparative study. Clin Drug Invest 2008; 28:495–500.

Morone NE, Lynch CS, Greco CM, Tindle HA, et al. “I Felt Like a New Person.” The effects of mindfulness meditation on older adults with chronic pain: Qualitative narrative analysis of diary entries. J Pain 2008; 9:841–848.

Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents 2008; 31:S112–S116.

Pearson AM, Blood EA, Frymoyer JW, Herkowitz H, et al. SPORT lumbar intervertebral disk herniation and back pain - Does treatment, location, or morphology matter? Spine 2008; 33:428–435.

Perrot S, Javier RM, Marty M, Le Jeunne C, et al. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies [Review]. Rheumatology 2008; 47:1117–1123.

Puzanovova M, Rudzinski E, Shirkey KC, Cherry R, et al. Sex, psychosocial factors, and reported symptoms influence referral for esophagogastroduodenoscopy and biopsy results in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2008; 47:54–60.

Randall C, Dickens A, White A, Sanders H, et al. Nettle sting for chronic knee pain: A randomised controlled pilot study. Complement Ther Med 2008; 16:66–72.

Raspe H, Hueppe A, Neuhauser H. Back pain, a communicable disease. Int J Epidemiol 2008; 37:69–74.

Richardson JC, Ong BN, Sim J. Experiencing and controlling time in everyday life with chronic widespread pain: a qualitative study - art. no. 3. BMC Musculoskeletal Disorder 2008:3.

Schaeffer AT. Epidemiology and evaluation of chronic pelvic pain syndrome in men. Int J Antimicrob Agents 2008; 31:S108–S111.

Slavin KV. Peripheral nerve stimulation for neuropathic pain. Neurotherapeutics 2008; 5:100–106.

Strassels SA, McNicol E, Suleman R. Pharmacotherapy of pain in older adults. Clin Geriatr Med 2008; 24:275.

Suh DC, Hunsche E, Shin HC, Mavros P. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. Rheumatology 2008; 47:458–463.

Underwood M, Ashby D, Carnes D, Castelnuovo E, et al. Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study [Review]. Health Technol Assess 2008.

Upasani VV, Caltoum C, Petcharaporn M, Bastrom TP, et al. Adolescent idiopathic scoliosis patients report increased pain at five years compared with two years after surgical treatment. Spine 2008; 33:1107–1112.

Wood LRJ, Peat G, Thomas E, Duncan R. The contribution of selected non-articular conditions to knee pain severity and associated disability in older adults. Osteoarth Cartilage 2008; 16:647–653.

Zacny JP, Lichtor SA. Motive for nonmedical use of prescription pain relievers in the National Survey on Drug Use and Health - Nonmedical use of prescription opioids: Furthering a meaningful research agenda - Reply to the commentaries. J Pain 2008; 9:494–496.

© 2009 Lippincott Williams & Wilkins, Inc.